Keywords: sanofi-synthelabo, sales, up, 3rd, quarter, newly-merged, french
Sanofi-Synthelabo sales up 9% in 3rd quarter
Article | 01 November 1999
Sanofi-Synthelabo, the newly-merged French pharmaceutical company, saysthat sales rose 7.8% to 3.93 billion euros ($4.20 billion) on a consolidated basis in the first ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
